ramucirumab (Cyramza)
ramucirumab is an FDA-licensed reference biologic from Eli Lilly and Company. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2014
Reference approved
Reference product
Cyramza ramucirumab
Eli Lilly and Company
- Approved
- Apr 21, 2014
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for ramucirumab, in chronological order.
Reference approval
Approval date of the reference ramucirumab product.
12 yr 3 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
22 d ago
Frequently asked questions
Are there biosimilars approved for ramucirumab (Cyramza)?
No 351(k) biosimilars or interchangeable biosimilars referencing ramucirumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.